With the advent of adoptive cellular therapy, chimeric antigen receptor (CAR)-T cell therapy
has gained widespread application in cancer treatment and has demonstrated significant …

The tumor microenvironment (TME) is closely associated with the therapeutic response and
clinical outcome of cancer drug therapies, which mainly include immunotherapy …

Patients with multiple myeloma (MM) were among the groups impacted more severely by the
COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality …

Despite significant breakthroughs in the understanding of immunological and
pathophysiological features for immune-mediated kidney diseases, a proportion of patients …

Severe combined immunodeficiency (SCID) encompasses rare primary immunodeficiency
disorders characterized by deficient T-cell development, which leads to a severely …

Background: The clinical success of autologous adoptive cell therapy (ACT) is substantial
but wide application is challenged by the quality and quantity of the patient's immune cells …

Adoptive cell therapy (ACT) enhances the patient's own immune cells' ability to identify and
eliminate cancer cells. Several immune cell types are currently being applied in autologous …

B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T-cell therapy
has significantly improved the treatment of relapsed or refractory multiple myeloma (MM) …

Background: The development and use of immunotherapy, particularly chimeric antigen
receptor T cells (CAR-T), has transformed cancer treatment. However, managing related …

Background The autologous anti–B-cell maturation antigen (BCMA) chimeric antigen
receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed …